FAQs about Mayzent
Mayzent was approved by the U.S. Food and Drug Administration in March 2019 to treat adults with relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting multiple sclerosis, and active secondary progressive multiple sclerosis.
Animal studies suggest that Mayzent can cause damage to a developing fetus. Anyone with the capacity to become pregnant should use effective birth control methods while on Mayzent and for 10 days after ceasing treatment.
Interactions between alcohol and Mayzent have not been reported. However, both can cause damage to the liver, and alcohol is also known to interfere with some disease symptoms and medications. It is recommended that patients discuss safe alcohol use with their healthcare team.
Benefits may be seen by some patients as soon as six months after starting treatment. In the BOLD trial, which compared Mayzent against a placebo in people with relapsing-remitting multiple sclerosis, significant reductions in the number of brain lesions and in relapse frequency were observed in as little as six months. However, as each person may respond very differently to a given medication, patients should talk with their care team to understand how Mayzent could help in their specific case.
Neither hair loss nor weight gain has been reported in clinical trials as side effects of Mayzent. Patients are advised to speak with their healthcare provider if they experience any unusual symptoms while on the medication.